Stratasys Ltd. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Equity (Tables)

Equity (Tables)

12 Months Ended

Dec. 31, 2020

Stockholders' Equity Note [Abstract]

Summary of RSUs and PSUs Activity

		Number of Options			Weighted Average Exercise Price
Options outstanding as of December 31, 2019		1,961,532		$	31.16
Granted		440,000			17.55
Exercised		(11,184	)		17.15
Forfeited		(287,819	)		33.55
Options outstanding as of December 31, 2020		2,102,529		$	28.06
Options exercisable as of December 31, 2020		1,691,217		$	30.64

Schedule of Stock Options Outstanding

								Options Outstanding												Options Exercisable
									Outstanding				Weighted- Average								Exercisable
									options at				Remaining				Weighted- Average				options at				Weighted- Average
Range of									December 31,				Contractual				Exercise				December 31,				Exercise
Exercise Prices									2020				Life in Years				Price				2020				Price
$	2.74		-	$	19.61				411,295				8.99			$	17.23				62,959			$	19.32
$	19.66		-	$	19.66				651,452				6.04				19.66				608,026				19.66
$	19.96		-	$	23.41				543,156				6.25				21.84				524,669				21.85
$	24.66		-	$	120.51				496,626				3.62				54.81				495,563				54.87
									2,102,529				6.10			$	28.06				1,691,217			$	30.64

Aggregate intrinsic value (U.S. $ in thousands)								$	2,213											$	820

Schedule of Stock Option Assumptions

		2020	2018
Risk-free interest rate		0.4%-1.8%	2.9%-3.1%
Expected option term (years)		5.0-5.1	5.3-5.5
Expected share price volatility		52.5%-52.8%	52.0%-52.2%
Dividend yield		-	-
Weighted average grant date fair value		$8.09	$11.49

Summary of RSUs and PSUs Activity

			Number of RSUs and PSUs				Weighted Average Grant Date Fair Value
Unvested RSUs and PSUs outstanding as of December 31, 2019			2,362,991			$	24.10
Granted			1,671,436				17.90
Vested			(677,249	)			23.19
Forfeited			(556,062	)			21.80
Unvested RSUs and PSUs outstanding as of December 31, 2020			2,801,116			$	21.08

Schedule of stock-based compensation expense

			2020				2019				2018
		(U.S. $ in thousands)

Cost of revenues		$	1,771			$	1,848			$	1,474
Research and development, net			6,102				5,167				3,215
Selling, general and administrative			12,331				13,549				10,997
Total stock-based compensation expenses		$	20,204			$	20,564			$	15,686

Schedule of accumulated other comprehensive loss

		Year ended December 31, 2020
			Net unrealized gain (loss) on cash flow hedges					Foreign currency translation adjustments					Total
		U.S. $ in thousands

Balance as of January 1, 2020		$	(10	)			$	(7,706	)			$	(7,716	)
Other comprehensive loss before reclassifications			(1,024	)				533					(490	)
Amounts reclassified from accumulated other comprehensive loss			(639	)				-					(639	)
Other comprehensive income (loss)			(1,663	)				533					(1,130	)
Balance as of December 31, 2020		$	(1,673	)			$	(7,173	)			$	(8,846	)

		Year ended December 31, 2019
			Net unrealized gain (loss) on cash flow hedges					Foreign currency translation adjustments					Total
		U.S. $ in thousands
Balance as of January 1, 2019		$	(627	)			$	(7,126	)			$	(7,753	)
Other comprehensive loss before reclassifications			1,548					(580	)				968
Amounts reclassified from accumulated other comprehensive loss			(931	)				0					(931	)
Other comprehensive income (loss)			617				$	(580	)				37
Balance as of December 31, 2019		$	(10	)				(7,706	)			$	(7,716	)

		Year ended December 31, 2018
			Net unrealized gain (loss) on cash flow hedges					Foreign currency translation adjustments					Total
		U.S. $ in thousands
Balance as of January 1, 2018		$	330				$	(7,353	)			$	(7,023	)
Other comprehensive loss before reclassifications			(1,814	)				(2,691	)				(4,505	)
Amounts reclassified from accumulated other comprehensive loss			857					2,918					3,775
Other comprehensive income (loss)			(957	)				227					(730	)
Balance as of December 31, 2018		$	(627	)			$	(7,126	)			$	(7,753	)